Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes
Kelvin Lingjet Tran, DO, Young In Park, DO, Shalin Pandya, DO, Navin John Muliyil, DO, Brandon David Jensen, DO, Kovin Huynh, DO, Quang T. Nguyen, DO, FACP, FACE, FTOS
It is estimated that 29.1 million people or 9.3% of the US population have diabetes, which contributes to considerable medical and financial burden.
The GLP-1 Receptor Agonists Are Cost-Effective for the Treatment of Type 2 Diabetes
Hyperkalemia, which is defined as an elevated serum potassium level (ie, >5.0 mEq/L), may be caused by a reduction in the renal excretion of potassium or an intracellular-to-extracellular shift in potassium that results from various acute clinical conditions. Although the kidney can adjust to a reduced number of nephrons and maintain normokalemia under steady-state conditions, it lacks the ability to respond to acute increases in potassium load and to adequately excrete potassium in patients with chronic kidney disease (CKD); the result in both cases is hyperkalemia.
Hyperkalemia in Chronic Diseases: A Serious Medical Condition in Need of Clinical Guidelines and New Treatment Options
Todd Williamson, PhD, MSc, Rajesh Kamalakar, MS, Augustina Ogbonnaya, MPH, Erin A. Zagadailov, PharmD, MS, Michael Eaddy, PharmD, PhD, Charlie Kreilick, MBA
Does a Free Office Visit Affect Primary Care–Seeking Behavior? A Study of New Exchange Health Plan Enrollees in Mississippi
Bettina M. Beech, DrPH, MPH, Tristan Cordier, MS, Laura E. Happe, PharmD, MPH, Laura Trunk, MD, Gilbert S. Haugh, MS, Richard Kwong, MPH, Vipin Gopal, PhD, Roy A. Beveridge, MD
In recent years, several health plans in the Health Insurance Marketplace exchange were offering free doctors’ visits to their members, with the hope of identifying illnesses before they become more difficult or more expensive to treat.
Patients’ Choice for Site of Care Motivated by More Than Cost Alone
Comparing Healthcare Utilization and Costs Among Medicaid-Insured Patients with Chronic Noncancer Pain with and without Opioid-Induced Constipation: A Retrospective Analysis
Tope Olufade, PhD, MPH, Amanda M. Kong, MPH, Nicole Princic, MS, Paul Juneau, MS, Rucha Kulkarni, MPH, Kui Zhang, MD, Catherine Datto, MD, MS
Chronic noncancer pain is a common and debilitating condition that affects approximately 30% of adults in the United States. The management of chronic pain is primarily aimed at relieving the pain and improving physical and emotional functions, although these are not achieved in a substantial number of patients.
The Opioid Epidemic: Healthcare Utilization and Cost Considerations
Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population
Jill R. Davis, MS, Bingcao Wu, MS, David M. Kern, PhD, Ozgur Tunceli, PhD, Kathleen M. Fox, PhD, John Horton, MS, Randall F. Legg, PharmD, MBA, Frank Trudo, MD, MBA
Chronic obstructive pulmonary disease (COPD) is characterized by declining lung function attributable to a combination of airway obstruction and inflammation.
When an Outcome Is Overdetermined: Nonadherence, Utilization, and the Impetus for Research in COPD
Breast cancer, the most common malignancy in women in the United States, is a serious disease associated with substantial medical and economic burden.
An Ounce of Prevention Is Not a Choice a Patient Gets to Make for Late-Stage Cancer
Chronic myelogenous leukemia (CML) is a hematologic cancer that occurs primarily in adults. Although CML can occur at any age, the median age at diagnosis is 64 years, and the incidence increases with age.
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
Joseph Tkacz, MS, Michael P. Ingham, MSc, Brenna L. Brady, PhD, Roxanne Meyer, PharmD, Charles Ruetsch, PhD
For many years, diseasemodifying antirheumatic drugs (DMARDs) have been the mainstay of RA treatment, reducing inflammation and preventing further joint deterioration and disease progression. In the past 15 years, biologic DMARDs have become available and have proved effective for reducing inflammation and managing the disease.
You Cannot Manage What You Cannot Measure
Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease
Rashad Carlton, PharmD, MSPH, Rajiv Mallick, PhD, Chelsey Campbell, PharmD, MBA, Aditya Raju, MS, BPharm, Thomas O'Donnell, MD, Michael Eaddy, PharmD, PhD, Michael Eaddy, PharmD, PhD, Michael F. Murphy, MD, PhD
Although varicose veins are considered by some policymakers to primarily be an aesthetic concern, varicosities and their resulting sequelae are primary contributors to the morbidity associated with chronic venous diseases.
A Teachable Moment in Health Benefits Design
Page 4 of 6
Results 31 - 40 of 51
Results 31 - 40 of 51